Blocking core fucosylation of epidermal growth factor (EGF) receptor prevents peritoneal fibrosis progression

Ren Fail. 2021 Dec;43(1):869-877. doi: 10.1080/0886022X.2021.1918557.

Abstract

Objective: Peritoneal fibrosis (PF) ultimately causes ultrafiltration failure and peritoneal dialysis (PD) termination, but there are few effective therapies for it. Core fucosylation, which is catalyzed by α1,6-fucosyltransferase (Fut8) in mammals, may play a crucial role in PF development. This study aims to assess the effects of inhibiting core fucosylation of epidermal growth factor (EGF) receptor on PF rats.

Methods: PF rats (established by 4.25% glucose dialysate) were treated with either an adenovirus-Fut8 short hairpin RNA (Fut8shRNA) or adenovirus-control. Masson's staining and net ultrafiltration were performed at week six. Fut8 level and core fucosylation of EGF receptor and collagen I in the peritoneal membrane were assessed, and EGF signaling was detected, including signal transducer and activator of transcription 3 (STAT3), nuclear factor kappa B (NF-κB) and their phosphorylation. Monocyte chemoattractant protein-1 (MCP-1) in peritoneal effluent was examined.

Results: Fut8 was upregulated in PF rats but decreased after Fut8shRNA treatment. EGF and EGF receptor expression was upregulated in PF rats, while core fucosylation of EGF receptor decreased after Fut8shRNA treatment. Masson's staining results showed an increase in peritoneal thickness in PF rats but a decrease after Fut8shRNA treatment. Fut8shRNA treatment increased net ultrafiltration, reduced the expression of collagen I and MCP-1 compared to PF rats. Fut8shRNA treatment suppressed phosphorylation of STAT3 and NF-κB in the peritoneal membrane of PF rats.

Conclusions: Fut8shRNA treatment ameliorated the fibrotic changes in PF rats. A potential mechanism may be that Fut8shRNA treatment inactivated EGF signaling pathway by suppressing the phosphorylation of STAT3 and NF-κB.

Keywords: Core fucosylation; epidermal growth factor receptor; peritoneal dialysis; peritoneal fibrosis.

MeSH terms

  • Animals
  • Chemokine CCL2 / metabolism
  • Dialysis Solutions
  • Disease Models, Animal
  • ErbB Receptors / drug effects
  • ErbB Receptors / metabolism*
  • Fucosyltransferases / genetics
  • Fucosyltransferases / pharmacology*
  • Glycosylation / drug effects*
  • Male
  • Peritoneal Dialysis / methods*
  • Peritoneal Fibrosis / metabolism
  • Peritoneal Fibrosis / pathology
  • Peritoneal Fibrosis / prevention & control*
  • Peritoneum / drug effects
  • Peritoneum / metabolism*
  • Peritoneum / pathology
  • Phosphorylation
  • RNA, Small Interfering / genetics
  • RNA, Small Interfering / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Signal Transduction / drug effects

Substances

  • Chemokine CCL2
  • Dialysis Solutions
  • RNA, Small Interfering
  • Fucosyltransferases
  • ErbB Receptors

Grants and funding

We acknowledge Liaoning Province for supporting the study. This work was supported by the Natural Science Foundation of Liaoning Province, China under Grant number 20180550285 #1, number 20180550897 #2, and the China Scholarship Council #3 under Grant number 201808210378.